Adding Sorafenib to Transarterial Chemoembolization in Hepatocellular Carcinoma

Key Points

  • The addition of sorafenib to transarterial chemoembolization did not improve progression-free survival in patients with unresectable hepatocellular carcinoma.
  • No significant benefit was observed in overall survival.

As reported in The Lancet Gastroenterology & Hepatology by Meyer et al, the UK phase III TACE 2 trial has shown no progression-free survival benefit with the addition of sorafenib (Nexavar) to transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. The trial was terminated early for futility.

Study Details

In the double-blind study, 313 patients with liver-confined disease from 20 UK sites were randomized between November 2010 and December 2015 to receive transarterial chemoembolization with drug-eluting beads and either sorafenib at 400 mg twice daily (n = 157) or placebo (n = 56). The primary endpoint was progression-free survival in the intent-to-treat population.

Progression-Free Survival

Formal interim futility analysis in July 2015 indicated a hazard ratio (HR) of 1.03 (P = .85), resulting in early trial closure. Median follow-up was 620 days.

Median progression-free survival was 238 days in the sorafenib group vs 235 in the placebo group (HR = 0.99, P = .94). Median overall survival was 631 vs 598 days (HR = 0.91, P = .57). Overall response rates were 36% vs 31% on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and 54% vs 52% on modified RECIST.

Adverse Events

The most common grade 3 or 4 adverse events in the sorafenib group were fatigue (18% vs 13%), abdominal pain (13% vs 8%), diarrhea (10% vs 3%), gastrointestinal disorders (11% vs 8%), and hand-foot skin reaction (8% vs 0%). Serious adverse events occurred in 41% vs 32% of patients.

The investigators concluded: “The addition of sorafenib to [drug-eluting bead]-[transarterial chemoembolization] does not improve progression-free survival in European patients with hepatocellular carcinoma. Alternative systemic therapies need to be assessed in combination with [transarterial chemoembolization] to improve patient outcomes.”

The study was funded by Bayer PLC and BTG PLC.

Tim Meyer, MBBS, of the University College London, is the corresponding author of The Lancet Gastroenterology & Hepatology article.

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.


Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.